Wells Fargo & Company Cuts Health Catalyst (NASDAQ:HCAT) Price Target to $10.00

Health Catalyst (NASDAQ:HCAT) had its price target cut by Wells Fargo & Company from $13.00 to $10.00 in a report released on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities analysts have also commented on HCAT. Citigroup decreased their price target on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Canaccord Genuity Group lowered their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Evercore ISI upped their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research report on Wednesday, January 8th. Finally, Stephens upped their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.91.

Health Catalyst Stock Up 3.2 %

HCAT opened at $5.79 on Tuesday. The firm has a market capitalization of $352.32 million, a P/E ratio of -4.29 and a beta of 1.36. Health Catalyst has a one year low of $5.35 and a one year high of $10.99. The company has a fifty day moving average price of $7.39 and a 200-day moving average price of $7.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. Health Catalyst’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.22) earnings per share. Equities research analysts expect that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $7.70, for a total value of $40,109.30. Following the sale, the chief operating officer now owns 129,690 shares in the company, valued at $998,613. The trade was a 3.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jason Alger sold 19,599 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the sale, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. This represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,169 shares of company stock valued at $639,174. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

A number of institutional investors have recently bought and sold shares of the stock. First Light Asset Management LLC grew its holdings in shares of Health Catalyst by 438.5% during the 2nd quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after acquiring an additional 3,221,408 shares during the period. Millennium Management LLC grew its stake in Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock worth $15,421,000 after purchasing an additional 1,184,131 shares during the period. Nepsis Inc. raised its holdings in Health Catalyst by 67.9% in the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after purchasing an additional 851,448 shares in the last quarter. Fred Alger Management LLC purchased a new position in Health Catalyst during the third quarter valued at $6,858,000. Finally, Portolan Capital Management LLC bought a new stake in shares of Health Catalyst during the 3rd quarter valued at $5,402,000. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.